In a commentary published Thursday, several top FDA officials offered insight into a key question when it comes to conducting clinical trials: How should real-world data translate into real-world evidence?
The authors, led by Motiur Rahman, a senior epidemiologist in the FDA’s drug center, explained how the terms real-world data (RWD) and real-world evidence (RWE) are frequently used inconsistently or interchangeably, including in submissions received by the agency.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.